Immutrin
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis.
$86.45M Series A ·
Led by Frazier Life Sciences · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredSep 20, 2019 (7 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $86.45M | fundraisingfox.com |
Timeline
- Website created
Team
MT
Mihriban Tuna Chief Executive OfficerRB
Robert Blaustein Chief Medical OfficerTH
Tolga Hassan Chief Financial Officer
Investors
CCambridge Enterprise Ventures
CCambridge Innovation Capital
FF-Prime Capital
FFrazier Life Scienceslead investor
PParkwalk Advisors
QQiming Venture Partners
SSR One
Companies like Immutrin
BBiosapienSeries A · Jan 2025
TTubulis$360M Series B+ · Oct 2025CCatalYm$150M Series B+ · Jul 2024
AAbcuro$66M Series B+ · Aug 2026
ZZag BioSeries A
HHuasaiboman Medical Cell Biology$29.97M Series B+ · Nov 2026
Other companies backed by Frazier Life Sciences
RRQ Bio$115M Series A · Jun 2026
AAngitia Bio$130M Series B+ · Feb 2026
AAirNexis Therapeutics$200M Series A · Jan 2026
AAspen Neuroscience$115M Series B+ · Nov 2025
- TTubulis$360M Series B+ · Oct 2025
AAlpha-9 Oncology$175M Series B+ · Oct 2024
Frazier Life Sciences portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/immutrin (get a free API key).